Ibalizumab monoclonal antibody is effective in real-world use
Dramatic decline in proportion of people with extensive resistance to anti-HIV medications
Fostemsavir salvage therapy continues to look good at 96 weeks
ART for treatment-experienced people with virological failure can omit NRTIs if three active drugs available
Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left
Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant people shows
Ibalizumab, active against highly resistant HIV, now approved in US
Fostemsavir controls viral load in half of people with highly drug-resistant HIV
